ResearchMoz

Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies

GBI Research
Published Date » 2013-09-23
No. Of Pages » N/A

GBI Research, the leading business intelligence provider, has released its latest research: Solid Tumors in Asia-Pacific Market to 2019 - New and Anticipated Approvals of Targeted Therapies to Trigger a Shift in Treatment Paradigm, which provides in-depth analysis of four key therapeutic indications within the Asia-Pacific (APAC) solid tumors market – bladder cancer, ovarian cancer, pancreatic cancer and prostate cancer – covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these four solid tumor types. 

The value of the solid tumors market in the APAC region amounted to an estimated $1 billion in 2012 and is expected to register a modest Compound Annual Growth Rate (CAGR) of 12.3% to reach $2.3 billion in 2019. The key drivers for growth in this market include: new product approvals in ovarian, pancreatic and prostate cancers; expected launches from the promising ovarian and prostate cancer pipelines; and increased market penetration due to the anticipated implementation of social insurance in China. Conversely, the growth of the market in this region could face some restricting influences, including: the recent implementation of a price ceiling on essential drugs in India; anticipated pricing restrictions in China; low access and penetration; and price erosion due to generic competition.
Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in the bladder cancer, ovarian cancer, pancreatic cancer and prostate cancer in the four APAC markets of Australia, China, India and Japan.

The report includes:

  • Disease overview, as well as treatment algorithms and treatment usage patterns
  • Market size and forecast for the APAC solid tumors market from 2012 to 2019
  • Major marketed products in the APAC region for all four solid tumor types covered
  • In-depth pipeline analysis for all four solid tumor types
  • Key drivers and restraints that have had and are expected to have a significant impact upon the market
  • Key licensing and co-development agreements in the solid tumors market

Reasons to Buy

The report will enhance your decision-making capability by allowing you to:

  • Align your product portfolio to the markets with high growth potential
  • Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
  • Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the solid tumors market
  • Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships
Table of Content

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Solid Tumors Market in Asia Pacific to 2019 - Introduction
2.1 Introduction

3 Solid Tumors Market in Asia Pacific to 2019 - Therapeutic Landscape
3.1 Bladder Cancer
3.1.1 Symptoms
3.1.2 Etiology
3.1.3 Pathophysiology
3.1.4 Diagnosis
3.1.5 Classification
3.1.6 Epidemiology
3.1.7 Prognosis and Disease Staging
3.1.8 Treatment Options
3.2 Ovarian Cancer
3.2.1 Symptoms
3.2.2 Etiology
3.2.3 Pathophysiology
3.2.4 Diagnosis
3.2.5 Classification
3.2.6 Epidemiology
3.2.7 Prognosis and Disease Staging
3.2.8 Treatment Options
3.3 Pancreatic Cancer
3.3.1 Symptoms
3.3.2 Etiology
3.3.3 Pathophysiology
3.3.4 Diagnosis
3.3.5 Classification
3.3.6 Epidemiology
3.3.7 Prognosis and Disease Staging
3.3.8 Treatment Algorithm
3.4 Prostate Cancer
3.4.1 Symptoms
3.4.2 Etiology
3.4.3 Pathophysiology
3.4.4 Co-Morbidities and Complications
3.4.5 Diagnosis
3.4.6 Classification
3.4.7 Epidemiology
3.4.8 Prognosis and Disease Staging
3.4.9 Treatment Options

4 Solid Tumors Market in Asia Pacific to 2019 - Marketed Products
4.1 Bladder Cancer
4.2 Ovarian Cancer
4.3 Pancreatic Cancer
4.4 Prostate Cancer
4.5 Key Marketed Products
4.5.1 Carboplatin
4.5.2 Cisplatin
4.5.3 Gemcitabine
4.5.4 Paclitaxel
4.5.5 Doxorubicin
4.5.6 Avastin (bevacizumab)
4.5.7 Tarceva (erlotinib)
4.5.8 Sutent (sunitinib)
4.5.9 Afinitor (everolimus)
4.5.10 Taxotere (docetaxel)
4.5.11 Zytiga (abiraterone acetate)
4.5.12 Jevtana (cabazitaxel)

5 Solid Tumors Market in Asia Pacific to 2019 - Pipeline Analysis
5.1 Bladder Cancer Pipeline
5.1.1 Overall Pipeline
5.1.2 Pipeline Analysis by Molecule Type
5.1.3 Pipeline Analysis by Mechanism of Action
5.2 Ovarian Cancer Pipeline
5.2.1 Overall Pipeline
5.2.2 Pipeline Analysis by Molecule Type
5.2.3 Pipeline Analysis by Mechanism of Action
5.3 Pancreatic Cancer Pipeline
5.3.1 Overall Pipeline
5.3.2 Pipeline Analysis by Molecule Type
5.3.3 Pipeline Analysis by Mechanism of Action
5.4 Prostate Cancer Pipeline
5.4.1 Overall Pipeline
5.4.2 Pipeline Analysis by Molecule Type
5.4.3 Pipeline Analysis by Mechanism of Action
5.5 Promising Drug Candidates in the Pipeline
5.5.1 Abraxane (albumin-bound paclitaxel)
5.5.2 AMG 386 (trebananib)
5.5.3 Votrient (pazopanib)
5.5.4 Xtandi (enzalutamide)

6 Solid Tumors Market in Asia Pacific to 2019- Market Forecast
6.1 Asia-Pacific Market
6.1.1 Treatment Usage Patterns
6.1.2 Annual Cost of Treatment
6.1.3 Market Size
6.2 India
6.2.1 Treatment Usage Patterns
6.2.2 Annual Cost of Treatment
6.2.3 Market Size
6.3 Australia
6.3.1 Treatment Usage Patterns
6.3.2 Annual Cost of Treatment
6.3.3 Market Size
6.4 China
6.4.1 Treatment Usage Patterns
6.4.2 Annual Cost of Treatment
6.4.3 Market Size
6.5 Japan
6.5.1 Treatment Usage Patterns
6.5.2 Annual Cost of Treatment
6.5.3 Market Size
6.6 Drivers and Barriers for the Solid Tumors Market in APAC
6.6.1 Drivers
6.6.2 Barriers

7 Solid Tumors Market in Asia Pacific to 2019 - Deals and Strategic Consolidations
7.1 Deals Analysis
7.2 Major Co-Development Deals
7.2.1 ScinoPharm Taiwan and Coland Enter into Agreement to Develop Generic Oncological Drugs
7.2.2 Bind Biosciences Enters into Agreement with Amgen to Develop Cancer Drugs
7.2.3 Merck Enters into Co-Development Agreement with Endocyte for Cancer Drug
7.2.4 Merck Serono Enters into Co-Development Agreement with Threshold Pharma for TH-302,
Pancreatic Cancer Drug
7.2.5 Seattle Genetics Exercises Option for Co-Development Agreement with Agensys (affiliate of
Astellas) for ASG-15ME
7.3 Major Licensing Deals
7.3.1 Spectrum Pharma Amends Licensing Agreement with Allergan for Apaziquone
7.3.2 Chugai Pharma Enters Into Licensing Agreement with Debiopharm Group for FF284
7.3.3 Baxter International Enters into Licensing Agreement with Onconova Therapeutics for
Rigosertib
7.3.4 Dyax Enters Into Licensing Agreement with Kadmon for Oncology Drug
7.3.5 Medigene Extends Licensing Agreement with Syncore for EndoTAG-1

8 Solid Tumors Market in Asia Pacific to 2019 - Appendix
8.1 Pipeline Drugs by Phase
8.1.1 Phase III
8.1.2 Pre-registration/NDA-filed
8.2 Market Forecasts to 2018
8.2.1 APAC
8.2.2 Australia
8.2.3 China
8.2.4 India
8.2.5 Japan
8.3 Market Definitions
8.4 Abbreviations
8.5 Sources
8.6 Research Methodology
8.6.1 Coverage
8.6.2 Secondary Research
8.6.3 Primary Research
8.6.4 Therapeutic Landscape
8.6.5 Geographical Landscape
8.6.6 Pipeline Analysis
8.7 Expert Panel Validation
8.8 Contact Us
8.9 Disclaimer

List of Tables


Table 1: Solid Tumors Market, Bladder Cancer, AJCC TNM Staging System, 2010
Table 2: Solid Tumors Market, Bladder Cancer, Treatment by Staging, 2013
Table 3: Solid Tumors Market, Ovarian Cancer, AJCC’s TNM and FIGO Staging Systems, 2013
Table 4: Solid Tumors Market, Pancreatic Cancer, AJCC TNM Staging System, 2013
Table 5: Solid Tumors Market, Prostate Cancer, AJCC Staging System, 2013
Table 6: Solid Tumors Market, Global, Pharmaceutical Pipeline (Phase III), 2013
Table 7: Solid Tumors Market, Global, Pharmaceutical Pipeline (Pre-registration/NDA-filed), 2013
Table 8: Solid Tumors Market, Asia-Pacific, Ovarian Cancer, Market Forecast, 2012–2019
Table 9: Solid Tumors Market, Asia-Pacific, Bladder Cancer, Market Forecast, 2012–2019
Table 10: Solid Tumors Market, Asia-Pacific, Pancreatic Cancer, Market Forecast, 2012–2019
Table 11: Solid Tumors Market, Asia-Pacific, Prostate Cancer, Market Forecast, 2012–2019
Table 12: Solid Tumors Market, Australia, Ovarian Cancer, Market Forecast, 2012–2019
Table 13: Solid Tumors Market, Australia, Bladder Cancer, Market Forecast, 2012–2019
Table 14: Solid Tumors Market, Australia, Pancreatic Cancer, Market Forecast, 2012–2019
Table 15: Solid Tumors Market, Australia, Prostate Cancer, Market Forecast, 2012–2019
Table 16: Solid Tumors Market, China, Ovarian Cancer, Market Forecast, 2012–2019
Table 17: Solid Tumors Market, China, Bladder Cancer, Market Forecast, 2012–2019
Table 18: Solid Tumors Market, China, Pancreatic Cancer, Market Forecast, 2012–2019
Table 19: Solid Tumors Market, China, Prostate Cancer, Market Forecast, 2012–2019
Table 20: Solid Tumors Market, India, Ovarian Cancer, Market Forecast, 2012–2019
Table 21: Solid Tumors Market, India, Bladder Cancer, Market Forecast, 2012–2019
Table 22: Solid Tumors Market, India, Pancreatic Cancer, Market Forecast, 2012–2019
Table 23: Solid Tumors Market, India, Prostate Cancer, Market Forecast, 2012–2019
Table 24: Solid Tumors Market, Japan, Ovarian Cancer, Market Forecast, 2012–2019
Table 25: Solid Tumors Market, Japan, Bladder Cancer, Market Forecast, 2012–2019
Table 26: Solid Tumors Market, Japan, Pancreatic Cancer, Market Forecast, 2012–2019
Table 27: Solid Tumors Market, Japan, Prostate Cancer, Market Forecast, 2012–2019

List of Figures


Figure 1: Solid Tumors Market, Asia-Pacific, Bladder Cancer, Epidemiology, 2012–2019
Figure 2: Solid Tumors Market, Bladder Cancer, Treatment Algorithm, Superficial and Stage I, 2013
Figure 3: Solid Tumors Market, Bladder Cancer, Treatment Algorithm, Stage II and III, 2013
Figure 4: Solid Tumors Market, Asia-Pacific, Ovarian Cancer, Epidemiology, 2012–2019
Figure 5: Solid Tumors Market, Ovarian Cancer, Treatment Algorithm, Stage I and II, 2013
Figure 6: Solid Tumors Market, Ovarian Cancer, Treatment Algorithm, Stage III and IV, 2013
Figure 7: Solid Tumors Market, Asia-Pacific, Pancreatic Cancer, Epidemiology, 2012–2019
Figure 8: Solid Tumors Market, Pancreatic Cancer, Treatment Algorithm, 2013
Figure 9: Solid Tumors Market, Asia-Pacific, Prostate Cancer, Epidemiology, 2012–2019
Figure 10: Solid Tumors Market, Prostate Cancer, Treatment Algorithm, 2013
Figure 11: Solid Tumors Market, Global, Avastin, Annual Sales ($m), 2006–2013e
Figure 12: Solid Tumors Market, Global, Tarceva, Annual Sales ($m), 2006–2013e
Figure 13: Solid Tumors Market, Global, Sutent, Annual Sales ($m), 2006–2013e
Figure 14: Solid Tumors Market, Global, Afinitor, Annual Sales ($m), 2009–2013e
Figure 15: Solid Tumors Market, Global, Zytiga, Annual Sales ($m), 2011–2013e
Figure 16: Solid Tumors Market, Global, Jevtana, Annual Sales ($m), 2010–2013e
Figure 17: Solid Tumors Market, Global, Bladder Cancer, Pipeline, 2013
Figure 18: Solid Tumors Market, Global, Bladder Cancer, Pipeline by Molecule Type, 2013
Figure 19: Solid Tumors Market, Global, Bladder Cancer, Pipeline by Mechanism of Action, 2013
Figure 20: Solid Tumors Market, Global, Ovarian Cancer, Pipeline, 2013
Figure 21: Solid Tumors Market, Global, Ovarian Cancer, Pipeline by Molecule Type, 2013
Figure 22: Solid Tumors Market, Global, Ovarian Cancer, Pipeline by Mechanism of Action, 2013
Figure 23: Solid Tumors Market, Global, Pancreatic Cancer, Pipeline, 2013
Figure 24: Solid Tumors Market, Global, Pancreatic Cancer, Pipeline by Molecule Type, 2013
Figure 25: Solid Tumors Market, Global, Pancreatic Cancer, Pipeline by Mechanism of Action, 2013
Figure 26: Solid Tumors Market, Global, Prostate Cancer, Pipeline, 2013
Figure 27: Solid Tumors Market, Global, Prostate Cancer, Pipeline by Molecule Type, 2013
Figure 28: Solid Tumors Market, Global, Prostate Cancer, Pipeline by Mechanism of Action, 2013
Figure 29: Solid Tumors Market, Asia-Pacific, Market Size ($m), 2012–2019
Figure 30: Solid Tumors Market, India, Market Size ($m), 2012–2019
Figure 31: Solid Tumors Market, Australia, Market Size ($m), 2012–2019
Figure 32: Solid Tumors Market, China, Market Size ($m), 2012–2019
Figure 33: Solid Tumors Market, Japan, Market Size ($m), 2012–2019
Figure 34: Solid Tumors Market, Global, Deals, 2006–2013
Figure 35: Solid Tumors Market, Global, Co-development Deals, 2006–2013
Figure 36: Solid Tumors Market, Global, Licensing Deals, 2006-2013
Figure 37: GBI Research Market Forecasting Model

Upcoming Reports:

Proppants Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2012 - 2018
By - Transparency Market Research
Hydraulic fracturing is the process of generating fractures in a rock solid surface using pressurized fracture fluids, and proppants keep this fracture open while drilling for oil. This process is crucial in the extraction of liquids and gas, which cannot be easily extracted through normal drilling methods. The extraction is usually conducted in low permeable reservoirs of oil and natural gas. A proppant is one of the integral fluids after water that helps in the process of fracturing and makes it easier to extract oil and natural gas from permeable reservoirs. The market is...
Electric Accumulators Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018
By - Transparency Market Research
Electric accumulators, commonly known as rechargeable batteries, are extensively used in various industrial sectors. They find applications in fields such as activated carbon, audio-visual equipments, and coating machines among many others. These accumulators include motor vehicle lead-acid, nickel-cadmium (NiCad) and the newly developed nickel-metal hydride (NiMH), and lithium ion polymer (LiPoly or LiPo) type batteries. The market for electric accumulators is concentrated in the European region followed by Asia Pacific. Regions such as North America and the rest of world exhibit an...
Functional Drinks Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018
By - Transparency Market Research
The functional drinks market is gaining momentum with improvements in quality and introduction of new products in the market. Introduction of energy drinks and Nutraceutical drinks have added to the growth of this market. Sports drinks with new and innovative flavors are playing a vital role in the steady growth of the functional drinks industry. Increasing consumer awareness towards health concerns is driving the energy drinks segments of this market. Energy drinks supply extra energy in the form of glucose. Nutraceutical drinks are meant for particular class and it is the smallest...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

India is Facing a Cancer Crisis
Apr 15, 2014  
India is currently facing a cancer crisis – reports a recent research carried out at the King’s college London, in collaboration with the Tata Memorial Cancer Centre, Mumbai.  The reasons estimated for this crisis comprise of increasing rates of smoking, unequal access to proper treatment and belated diagnosis.  Every year, India witnesses around one...
Microparticle Tags to Check Counterfeit Goods Invented
Apr 14, 2014  
Researchers from the Massachusetts Institute of Technology have invented a new set of microparticles that can easily be read by smartphones and establish the authenticity of currency, electronic items and luxury goods.  This strategy is among those countless measures taken by big brands and companies to label their legitimate products in order to stop illegal copies of the...
USFDA Approves Lupins Generic Diabetic Drug
Apr 10, 2014  
The United States Food and Drugs Administration (USFDA) has finally approved Lupin Pharmaceuticals Inc (LPI), the American subsidiary of Indian drug manufacturers Lupin Ltd, to sell Pioglitazone Tablets in the U.S market. The approval has been granted first for fiscal 2015.  Pioglitazone is a generic medicine used for managing diabetes and is a version of Actos tablets...
Infrared Sensors can Soon Be Used to Develop Night-Vision Lenses - A New Discovery Confirms
Apr 8, 2014  
People who fear the dark may soon have a reason to rejoice – an infrared sensor that can eventually be used for mechanizing night-vision lenses has been developed. This effectively means that one can also see through dark with the help of these lenses.  This technology seems possible all due to graphene, a layer of tightly packed carbon atoms that has allowed the creation of...
Ontarios thanks Sustainable Development Technology Canada for Clean Tech Ecosystem Movements
Apr 8, 2014  
Sustainable Development Technology Canada has leveraged an extra $2.2 billion in funding from project partners that also includes global clean technology companies.  Sustainable Development Technology Canada (SDTC) is energizing and evolving the development and demonstration of a clean technology ecosystem. They are the vital contributors to the prominent concentration of clean...